X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (98) 98
hematology (76) 76
index medicus (74) 74
male (56) 56
adult (53) 53
middle aged (53) 53
female (52) 52
aged (46) 46
leukemia, myeloid, acute - genetics (46) 46
oncology (46) 46
prognosis (44) 44
acute myeloid-leukemia (35) 35
aged, 80 and over (35) 35
acute myeloid leukemia (31) 31
mutation (30) 30
adolescent (29) 29
acute myelogenous leukemia (28) 28
cancer (28) 28
leukemia (28) 28
young adult (26) 26
animals (23) 23
leukemia, myeloid, acute - mortality (20) 20
mice (20) 20
aml (19) 19
fms-like tyrosine kinase 3 - genetics (19) 19
gene expression (19) 19
hemic and lymphatic diseases (18) 18
leukemia, myeloid, acute - pathology (18) 18
abridged index medicus (17) 17
leukemia, myeloid, acute - metabolism (17) 17
survival (17) 17
treatment outcome (17) 17
internal tandem duplication (15) 15
mutations (15) 15
survival analysis (15) 15
article (14) 14
disease-free survival (14) 14
leukemia, myeloid, acute - drug therapy (14) 14
myeloid leukemia (14) 14
risk factors (14) 14
diagnosis (13) 13
expression (13) 13
nuclear proteins - genetics (13) 13
analysis (12) 12
chemotherapy (12) 12
leukemia, myeloid, acute - diagnosis (12) 12
medizin (12) 12
minimal residual disease (12) 12
multidisciplinary sciences (12) 12
cell line, tumor (11) 11
medicine & public health (11) 11
recurrence (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
flow cytometry (10) 10
gene expression profiling (10) 10
genetic aspects (10) 10
karyotyping (10) 10
leukemia, myeloid, acute - therapy (10) 10
normal karyotype (10) 10
patients (10) 10
remission induction (10) 10
adults (9) 9
constitutive activation (9) 9
follow-up studies (9) 9
gene (9) 9
gene expression regulation, neoplastic (9) 9
gene-mutations (9) 9
health aspects (9) 9
kaplan-meier estimate (9) 9
phosphorylation (9) 9
transplantation (9) 9
acute promyelocytic leukemia (8) 8
age factors (8) 8
c-kit (8) 8
cell line (8) 8
enzyme inhibitors - pharmacology (8) 8
favorable prognosis (8) 8
fms-like tyrosine kinase 3 - metabolism (8) 8
gene expression regulation, leukemic (8) 8
hematology, oncology and palliative medicine (8) 8
high-dose cytarabine (8) 8
internal medicine (8) 8
mutation - genetics (8) 8
neoplasms (8) 8
oncogene proteins, fusion - genetics (8) 8
patient outcomes (8) 8
recommendations (8) 8
research (8) 8
signal transduction (8) 8
stem cells (8) 8
survival rate (8) 8
transfection (8) 8
acute disease (7) 7
apoptosis - drug effects (7) 7
biomarkers, tumor - genetics (7) 7
blotting, western (7) 7
care and treatment (7) 7
cell biology (7) 7
chromosome aberrations (7) 7
dna mutational analysis (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 2019, Volume 33, Issue 5, pp. 1124 - 1134
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2000 - 2008
Journal Article
Blood, ISSN 0006-4971, 12/2011, Volume 118, Issue 26, pp. 6760 - 6768
Journal Article
European Journal of Haematology, ISSN 0902-4441, 02/2018, Volume 100, Issue 2, pp. 154 - 162
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 07/2017, Volume 142, Issue 13, pp. 942 - 943
Journal Article
Annals of Hematology, ISSN 0939-5555, 1/2013, Volume 92, Issue 1, pp. 41 - 52
Despite improvement of prognosis, older age remains a negative prognostic factor in acute promyelocytic leukemia (APL). Reports on disease characteristics and... 
Acute promyelocytic leukemia | Treatment | Medicine & Public Health | Hematology | Oncology | Early death | Elderly patients | IDARUBICIN | RISK-ADAPTED TREATMENT | CONSOLIDATION CHEMOTHERAPY | PROGNOSTIC-FACTORS | MULTICENTER EXPERIENCE | TRANS-RETINOIC ACID | EARLY DEATH RATE | ARSENIC TRIOXIDE | ANTHRACYCLINE MONOCHEMOTHERAPY | HEMATOLOGY | GIMEMA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Age Factors | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Male | Risk | Leukemia, Promyelocytic, Acute - epidemiology | Aged, 80 and over | Female | Leukocyte Count | Maintenance Chemotherapy | Daunorubicin - administration & dosage | Oxides - administration & dosage | Multicenter Studies as Topic - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Tretinoin - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Leukemia, Promyelocytic, Acute - blood | Remission Induction | Cytarabine - administration & dosage | Germany - epidemiology | Disease-Free Survival | Arsenicals - administration & dosage | Thioguanine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Leukemia, Promyelocytic, Acute - mortality | Aged | Leukemia, Promyelocytic, Acute - genetics | Leukemia, Promyelocytic, Acute - drug therapy | Anthracyclines | Arsenic | Patient outcomes | Analysis | Mortality | Aged patients | Universities and colleges | Tretinoin | Index Medicus | Original
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 09/2018, Volume 143, Issue 18, pp. 1297 - 1303
AbstractThere are several changes in the revised WHO classification for acute leukemia. The latest version of the European Leukemia Network (ELN)-risk... 
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 09/2018, Volume 143, Issue 18, pp. 1297 - 1303
Abstract There are several changes in the revised WHO classification for acute leukemia. The latest version of the European Leukemia Network (ELN)-risk... 
Dossier
Journal Article
Science, ISSN 0036-8075, 12/2017, Volume 358, Issue 6367, p. eaan4368
Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly observed, requiring thorough target deconvolution to understand drug... 
REFINEMENT | PROTEIN | CHEMICAL PROTEOMICS | INHIBITOR SELECTIVITY | DATA QUALITY | QUANTIFICATION | MULTIDISCIPLINARY SCIENCES | INTEGRATIVE GENOMICS VIEWER | SALT-INDUCIBLE KINASES | CANCER | COMPREHENSIVE ANALYSIS | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Lung Neoplasms - drug therapy | Lung Neoplasms - enzymology | Cytokines - metabolism | Humans | Drug Discovery - methods | Antineoplastic Agents - chemistry | Molecular Targeted Therapy | Xenograft Model Antitumor Assays | Leukemia, Myeloid, Acute - enzymology | Protein Kinase Inhibitors - chemistry | Animals | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myeloid, Acute - drug therapy | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Proteomics - methods | Salts | Target recognition | Lung cancer | Selectivity | Drug development | Cancer therapies | Signal transduction | Biomolecules | Protein-tyrosine kinase | Tyrosine | Medical research | Imatinib | Decision making | Medical treatment | Mass spectroscopy | Tumor necrosis factor-α | Embryos | Bruton's tyrosine kinase | Mode of action | Side effects | Inhibitors | Interleukin 10 | Affinity | Drug discovery | Mass spectrometry | Acute myeloid leukemia | Drugs | Deregulation | Leukemia | Interleukin | Medical services | Clinical trials | Leucine | Kinases | Biological effects | Epidermal growth factor | Salt-inducible kinase | Xenografts | Cell survival | Epidermal growth factor receptors | Research & development--R&D | Therapeutic applications | Myeloid leukemia | Markers | Data processing | Lead compounds | Leucine zipper proteins | Signaling | Proteomics | Cancer
Journal Article
Annals of Hematology, ISSN 0939-5555, 12/2015, Volume 94, Issue 12, pp. 2015 - 2024
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 2018, Volume 143, Issue 18, pp. 1297 - 1303
Journal Article
Haematologica, ISSN 0390-6078, 09/2014, Volume 99, Issue 9, pp. 1441 - 1447
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1518 - 1518
Abstract Introduction Leukemia-initiating cells (LIC) are considered the source of therapy resistance and relapse, including in acute myeloid leukemia (AML).... 
Journal Article